Haploidentical Hematopoietic Stem Cell Transplantation With Anti-Thymocyte Globulin in the Treatment of Older Adults With Hematological Malignancy.

OBJECTIVES

Studies on the efficacy and safety of haploidentical hematopoietic stem cell transplantation (haplo-SCT) with anti-thymocyte globulin (ATG) in patients aged ≥ 60 years remain limited.

METHODS

We performed a study presenting data from 54 patients aged ≥ 60 years with hematologic malignancies who underwent haplo-SCT with ATG.

RESULTS

The median follow-up was 15 months. The median overall survival (OS) at 1-, 2-, and 3-year was 68.4%, 51.2%, and 47.6%, respectively. The cumulative incidence of non-relapse mortality (NRM) at 1 and 3 years post haplo-SCT was 22.9% and 34.8%, respectively. The cumulative incidence of 1- and 3-years relapse rate was 11.3% and 25.6%. The 100-day cumulative incidence of Grade II-IV acute graft-versus-host disease (aGvHD) was 23.1%, while the 3-year cumulative incidence of extensive chronic graft-versus-host disease (cGvHD) was 10.4%. The absence of complete remission at the time of haplo-SCT was identified as a risk factor for OS, relapse, and NRM.

CONCLUSIONS

Our study suggests that haplo-SCT with ATG is a safe and effective treatment option for patients aged ≥ 60 years. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.